topic

580 Mapping interstitial fluid flow in the brain to improve CAR T cell trafficking and efficacy
Margarita Gutova, Ryan Woodall, Eric Ma, Cora Esparza, Vanessa Salvary, Brenda Aguilar, Renate Starr, Behnam Badie, Darya Alizadeh, Jennifer M Munson, Russell C Rockne, Christine Brown

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A660; DOI: 10.1136/jitc-2023-SITC2023.0580
581 Final analysis of 2-THE-TOP: a phase 2 study of TTFields (Optune) plus pembrolizumab plus maintenance temozolomide (TMZ) in patients with newly diagnosed glioblastoma
David Tran, Ashley Ghiaseddin, Dongjiang Chen, Son Le

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A661; DOI: 10.1136/jitc-2023-SITC2023.0581
582 Analysis of the HR+/HER2- breast cancer tumor microenvironment following immune priming with pelareorep and atezolizumab using imaging mass cytometry – Results from the AWARE-1 trial
Julian Olea, Homa Dadrastoussi, Eduardo Fernandez Hernandez, Hugo Lara Martinez, Kaijin Wu, Houra Loghmani, Thomas Heineman, Richard Trauger, Matt Coffey, Fernando Salvador, Joaquín Gavilá, Tomás Pascual, Luis Manso, Aleix Prat, Akil Merchant, Kevin Kelly

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A662; DOI: 10.1136/jitc-2023-SITC2023.0582
583 Abstract withdrawn
Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A663; DOI: 10.1136/jitc-2023-SITC2023.0583
584 Phase I/II study to evaluate the safety and tolerability of avelumab in combination with other anti-cancer therapies in patients with advanced malignancies
Jibran Ahmed, Anne Knisely, Bettzy Stephen, Yali Yang, Juhee Song, Anas Alshawa, Abdulrazzak Zarifa, Van Morris, Milind Javle, Robert A Wolff, Funda Meric-Bernstam, Shubham Pant, Jordi Rodon, Aung Naing

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A664; DOI: 10.1136/jitc-2023-SITC2023.0584
585 Ofranergene obadenovec (VB-111) in combination with nivolumab in patients with microsatellite stable colorectal liver metastases: a single-center, single-arm phase II trial
Kelley Coffman, Yuta Myojin, Cecilia Monge, Changqing Xie, Donna M Hrones, Bradford J Wood, Elliott B Levy, David E Kleiner, Seth M Steinberg, Bernadette Redd, Tim F Greten

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A665; DOI: 10.1136/jitc-2023-SITC2023.0585
586 Phase II study of Telomelysin (OBP-301) in combination with pembrolizumab in gastroesophageal (GEA) adenocarcinoma
Sandipto Sarkar, Sahrish Khan, Jennifer Rachel Eads, Reem Sharaiha, David Carr-Locke, Lillian Chang, Gregory Ginsberg, Lisa DiCicco, Luis Garcia-Marcano, Erika Hissong, Doron Betel, Manish Shah

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A666; DOI: 10.1136/jitc-2023-SITC2023.0586
587 Nivolumab increased vaccine induced T-cell infiltration in Prostate cancer
Wiem Lassoued, Daniel Burnett, Kenneth Canubas, Shania Bailey, Jennifer Marte, Nikki William, Amy Hankin, Manuk Manukyan, Michell Manu, William Dahut, Peter Pinto, Fatima Karzai, Ravi Madan, Houssein Abdul Sater, James L Gulley

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A667; DOI: 10.1136/jitc-2023-SITC2023.0587
588 Dostarlimab + chemotherapy for the treatment of primary advanced or recurrent endometrial cancer (pA/rEC) in the RUBY trial: post hoc analysis of the costs of grade ≥3 adverse events (AEs)
Solomon J Lubinga, Tilman Payer, Meghann Gregg, Lydia Lee, Odette Allonby, Llenalia García-Fernández, Jean Hurteau

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A668-A669; DOI: 10.1136/jitc-2023-SITC2023.0588
589 RUBY trial post hoc analysis of number needed to treat and incremental costs per outcome of dostarlimab + carboplatin-paclitaxel (CP) vs placebo + CP for primary advanced/recurrent endometrial cancer
Solomon J Lubinga, Tilman Payer, Lydia Lee, Meghann Gregg, Odette Allonby, Llenalia García-Fernández, Jean Hurteau

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A670; DOI: 10.1136/jitc-2023-SITC2023.0589

Main menu

topic

Pages

Log in using your username and password

Main menu

Log in using your username and password

You are here

topic

Pages